Aeglea amends bylaws for universal proxy rules, DGCL changes, and meeting procedures

Spyre Therapeutics, Inc.

Board adopted amended bylaws effective December 15, 2022.
Revised advance notice provisions: requires additional disclosures, limits nominees to directors up for election, and mandates nominee interviews.
Added compliance measures for SEC Rule 14a-19 universal proxy, including certification and notice requirements.
Updated adjournment procedures and stockholder meeting conduct; added emergency bylaw for quorum failure.
Conformed notice provisions to DGCL electronic transmission amendments.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Spyre Therapeutics, Inc.: Amended and restated bylaws to conform to DGCL amendments and universal proxy rules, including revisions to stockholder meeting procedures, advance notice provisions, and emergency bylaws (effective 2022-12-15).

Change: bylaw amendment
Effective: 2022-12-15

Exact text from the filing

On December 15, 2022, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “ DGCL ”), and a periodic review of the bylaws of Aeglea Biotherapeutics, Inc. (the “ Company ”), the Company’s board of directors (the “ Board ”) approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), which became immediately effective.

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-308316

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.